3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Motor Activity
22
Neoplasms
13
Breast Neoplasms
9
Lung Neoplasms
6
Pancreatic Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Recurrence
2
Peripheral Nervous System Diseases
2
Obesity
2
Neoplasm Metastasis
2
Lymphoma
2
Lymphedema
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcopenia
1
Rectal Neoplasms
1
Quality of Life
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Neurotoxicity Syndromes
1
Neurocognitive Disorders
1
Neoplasms, Plasma Cell
1
Muscular Atrophy
1
Multiple Myeloma
1
Interventions
Gemcitabine
31
pembrolizumab
20
Cisplatin
20
Magnetic Resonance Spectroscopy
18
Specimen Handling
16
durvalumab
11
Mitomycin
11
enfortumab vedotin
9
avelumab
9
Nivolumab
9
Cystoscopy
9
Fluorouracil
8
Radiation
7
Carboplatin
7
Radiotherapy
6
Immunoglobulin G
6
Docetaxel
6
Disulfides
6
Cystectomy
6
Transurethral Resection of Bladder
5
Mitozytrex
5
Biopsy
5
sacituzumab govitecan
4
erdafitinib
4
dehydroftorafur
4
atezolizumab
4
Standard of Care
4
Platinum
4
1,2-diaminocyclohexaneplatinum II citrate
4
tremelimumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Exercise
×
90 days
×
Clear all
NCT07548476
2026-05-04
ACE
Dana-Farber Cancer Institute
Phase NA
Not yet recruiting
50 enrolled